A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2

Despite substantial advances in the treatment of acute myeloid leukemia (AML), only 30% of patients survive more than 5 years. Therefore, new therapeutics are much needed. Here, we present a novel therapeutic strategy targeting PR1, an HLA-A2 restricted myeloid leukemia antigen. Previously, we have...

Descripción completa

Detalles Bibliográficos
Autores principales: Herrmann, Amanda C., Im, Jin S., Pareek, Sumedha, Ruiz-Vasquez, Wilfredo, Lu, Sijie, Sergeeva, Anna, Mehrens, Jennifer, He, Hong, Alatrash, Gheath, Sukhumalchandra, Pariya, St. John, Lisa, Clise-Dwyer, Karen, Zha, Dongxing, Molldrem, Jeffrey J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345694/
https://www.ncbi.nlm.nih.gov/pubmed/30713535
http://dx.doi.org/10.3389/fimmu.2018.03153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345694/
https://www.ncbi.nlm.nih.gov/pubmed/30713535
http://dx.doi.org/10.3389/fimmu.2018.03153

Ejemplares similares